Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

FATE

Fate Therapeutics Inc

Dec 12 • 12:24PM ET

2.06

Dollar change -0.12
Percentage change -5.73	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD CRSP BLUE SRPT EDIT NTLA CLLS SGMO CARA VTVT

| Held by: VTI IWM XBI VXF IWN DFAT KOMP VTWO SCHA DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.65	Insider Own	13.99%	Shs Outstand	113.88M	Perf Week	-13.66%
Market Cap	234.05M	Forward P/E	-	EPS next Y	-1.67	Insider Trans	-0.00%	Shs Float	97.96M	Perf Month	-13.66%
Income	-178.23M	PEG	-	EPS next Q	-0.44	Inst Own	89.44%	Short Float	11.58%	Perf Quarter	-48.88%
Sales	13.45M	P/S	17.40	EPS this Y	0.38%	Inst Trans	-5.32%	Short Ratio	4.93	Perf Half Y	-45.35%
Book/sh	3.18	P/B	0.65	EPS next Y	-2.26%	ROA	-34.32%	Short Interest	11.35M	Perf Year	-14.38%
Cash/sh	2.61	P/C	0.79	EPS next 5Y	-	ROE	-46.59%	52W Range	1.96 - 8.83	Perf YTD	-45.05%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-6.65%	ROI	-39.22%	52W High	-76.73%	Beta	1.93
Dividend TTM	-	Quick Ratio	8.29	Sales past 5Y	87.14%	Gross Margin	-41.55%	52W Low	4.85%	ATR (14)	0.34
Dividend Ex-Date	-	Current Ratio	8.29	EPS Y/Y TTM	6.37%	Oper. Margin	-1462.06%	RSI (14)	39.51	Volatility	12.14% 16.07%
Employees	181	Debt/Eq	0.27	Sales Y/Y TTM	-87.34%	Profit Margin	-1325.43%	Recom	2.53	Target Price	6.33
Option/Short	Yes / Yes	LT Debt/Eq	0.25	EPS Q/Q	11.67%	Payout	-	Rel Volume	2.05	Prev Close	2.18
Sales Surprise	147.44%	EPS Surprise	3.96%	Sales Q/Q	58.13%	Earnings	Nov 12 AMC	Avg Volume	2.30M	Price	2.06
SMA20	-16.10%	SMA50	-23.47%	SMA200	-49.92%	Trades		Volume	2,238,796	Change	-5.73%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-24	Upgrade	Piper Sandler	Neutral → Overweight	$4 → $6
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$6
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral	$115 → $7
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral	$42 → $7
Jan-06-23	Downgrade	Truist	Buy → Hold	$46 → $7
Jan-06-23	Downgrade	Stifel	Buy → Hold	$107 → $5.30
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral	$71 → $12
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$72 → $4
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$20 → $7
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell	$10
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight	$98 → $45
Oct-10-22	Initiated	Canaccord Genuity	Buy	$42
Aug-18-22	Resumed	Wells Fargo	Overweight	$90
Jul-28-22	Initiated	Needham	Hold
Jul-11-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$50 → $47
Jun-03-22	Initiated	Robert W. Baird	Neutral	$28

Show Previous Ratings

Dec-09-24 04:01PM	Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus (GlobeNewswire) -16.18%
Dec-03-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.15%
Dec-02-24 09:55AM	Fate Therapeutics makes Bob Valamehr president and CEO (Pharmaceutical Technology) -6.62%
Nov-29-24 01:05PM	Fate Therapeutics Announces Leadership Transition (GlobeNewswire)
Nov-26-24 04:01PM	Fate Therapeutics to Present at Upcoming December Investor Conferences (GlobeNewswire) +10.74% +18.28%
08:05AM	Loading…
Nov-18-24 08:05AM	Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence (GlobeNewswire) +12.38%
08:00AM	Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence (GlobeNewswire)
Nov-12-24 05:20PM	Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.03% -8.82%
04:18PM	Fate Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Nov-09-24 01:30PM	Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting (GlobeNewswire)
Nov-08-24 04:01PM	Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting (GlobeNewswire) -5.10% +5.79%
Nov-04-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.58%
Oct-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-24 04:01PM	Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference (GlobeNewswire) +7.49%
11:30AM	Loading…
11:30AM	Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? (Zacks)
Aug-16-24 12:00PM	All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy (Zacks)
Aug-13-24 05:25PM	Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:25PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Aug-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.12% -9.50%
Jul-31-24 08:00AM	Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors (GlobeNewswire)
Jul-21-24 05:37AM	Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? (Motley Fool)
Jul-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 04:01PM	Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-24 10:48AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 02:50PM	Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ... (GuruFocus.com)
10:36AM	Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating (MT Newswires)
08:22AM	Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating (MT Newswires)
08:58PM	Loading…
May-09-24 08:58PM	FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.41%
05:25PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:21PM	Fate Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
08:30AM	Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program (GlobeNewswire)
May-06-24 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates (GlobeNewswire)
May-03-24 04:30PM	Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting (GlobeNewswire)
Apr-22-24 04:30PM	Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting (GlobeNewswire) -5.02%
Apr-06-24 02:17AM	Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress (Zacks)
Apr-04-24 11:30PM	NOTICE TO LONG-TERM SHAREHOLDERS OF FATE THERAPEUTICS, INC. (FATE): GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON YOUR BEHALF (Newsfile)
Apr-03-24 08:00AM	Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-24 11:30AM	Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound? (Zacks) +7.00%
Mar-19-24 08:44AM	Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement (GlobeNewswire)
Mar-05-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.15%
Mar-01-24 08:09AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.17%
08:00AM	Fate Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Feb-27-24 09:16AM	Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y (Zacks) +7.34%
08:07AM	Q4 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-24 05:10PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:35PM	Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
04:08PM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-19-24 10:00AM	Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-15-24 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.09%
Feb-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-30-24 07:54AM	Fate Therapeutics (FATE) Soars 25.4%: Is Further Upside Left in the Stock? (Zacks)
Jan-29-24 02:53PM	Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock (InvestorPlace) +25.44%
Jan-08-24 08:00AM	Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors (GlobeNewswire) +9.28%
Dec-22-23 12:00PM	Fate Therapeutics (FATE) Upgraded to Buy: Here's Why (Zacks)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-13-23 05:00PM	Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.67% +11.19%
Dec-08-23 11:30AM	Fate Therapeutics (FATE) Up 10.3% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-09-23 01:18PM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2023 Earnings Call Transcript (Insider Monkey) -8.58%
Nov-08-23 06:18PM	Fate Therapeutics Inc (FATE) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:08PM	Fate Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Oct-25-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results (GlobeNewswire) -7.22%
Sep-15-23 06:01AM	Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength? (Zacks) -6.78%
Sep-07-23 11:30AM	Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report? (Zacks)
Aug-31-23 08:00AM	Fate Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-29-23 07:30AM	16 Most Shorted Stocks Right Now (Insider Monkey)
Aug-09-23 12:12PM	FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss (Zacks)
11:04AM	Q2 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-08-23 05:15PM	Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:11PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Jul-28-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-22-23 08:35AM	One Fate Therapeutics Insider Raised Stake By 83% In Previous Year (Simply Wall St.)
Jul-01-23 10:33AM	We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-16-23 03:53PM	Why Shares of Fate Therapeutics Soared This Week (Motley Fool)
Jun-14-23 06:42AM	Editas (EDIT) Surges 15.5%: Is This an Indication of Further Gains? (Zacks)
Jun-08-23 11:30AM	Halozyme Therapeutics (HALO) Up 0.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-07-23 11:30AM	Why Is Axsome (AXSM) Down 2.5% Since Last Earnings Report? (Zacks)
Jun-04-23 08:27AM	Fate Therapeutics, Inc.'s (NASDAQ:FATE) Low P/S No Reason For Excitement (Simply Wall St.)
Jun-02-23 11:31AM	Fate Therapeutics (FATE) Down 17.8% Since Last Earnings Report: Can It Rebound? (Zacks)
May-31-23 08:00AM	Fate Therapeutics to Present at Upcoming June Investor Conferences (GlobeNewswire)
May-25-23 10:49AM	Cathie Wood is Selling These 12 Stocks in 2023 (Insider Monkey) -5.62%
May-08-23 06:05AM	Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging Higher (Simply Wall St.)
May-04-23 11:59AM	FATE Incurs Narrower-Than-Expected Q1 Loss on Lower Expenses (Zacks)
11:22AM	Q1 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.76%
04:11PM	Fate Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:01PM	Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
12:00PM	Fate Therapeutics (FATE) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-27-23 10:03AM	Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-26-23 10:02AM	Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-24-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results (GlobeNewswire)
Apr-12-23 07:20AM	Shareholders in Fate Therapeutics (NASDAQ:FATE) are in the red if they invested a year ago (Simply Wall St.)

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Xu Yuan	Director	Aug 06 '24	Sale	4.23	633	2,678	8,669	Aug 07 04:01 PM
Xu Yuan	Director	Aug 06 '24	Proposed Sale	4.23	633	2,678		Aug 06 10:34 AM
Dulac Edward J III	Chief Financial Officer	Mar 04 '24	Sale	7.77	2,447	19,013	101,479	Mar 05 04:24 PM
Dulac Edward J III	Chief Financial Officer	Jan 29 '24	Sale	5.00	1,849	9,245	103,926	Jan 30 04:01 PM
TAHL CINDY	General Counsel and Secretary	Jan 09 '24	Sale	4.37	10,874	47,519	142,361	Jan 10 04:30 PM
Valamehr Bahram	Chief R&D Officer	Jan 09 '24	Sale	4.38	11,271	49,367	158,069	Jan 10 04:30 PM
Wolchko J Scott	President and CEO	Jan 09 '24	Sale	4.37	14,391	62,889	371,248	Jan 10 04:29 PM
Dulac Edward J III	Chief Financial Officer	Jan 09 '24	Sale	4.37	7,028	30,712	105,775	Jan 10 04:29 PM
Dulac Edward J III	Chief Financial Officer	Jan 02 '24	Sale	3.66	5,182	18,966	112,803	Jan 03 04:03 PM
Redmile Group, LLC	Director	Dec 26 '23	Buy	3.72	44,630	166,024	13,180,388	Dec 28 09:30 PM
Dulac Edward J III	Chief Financial Officer	Dec 18 '23	Sale	3.50	1,585	5,548	117,985	Dec 19 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FATE

Fate Therapeutics Inc

Upgrade your FINVIZ experience